Suppliers and packagers for AMONDYS 45

AMONDYS 45

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026	NDA	Sarepta Therapeutics, Inc.	60923-227-02	1 VIAL, SINGLE-USE in 1 CARTON (60923-227-02) / 2 mL in 1 VIAL, SINGLE-USE	2021-02-25

Suppliers for the Pharmaceutical Drug: AMONDYS 45

Last updated: August 3, 2025

Introduction

AMONDYS 45 (casimersen) is a groundbreaking FDA-approved antisense oligonucleotide (ASO) developed by Sarepta Therapeutics to treat Duchenne muscular dystrophy (DMD) caused by specific genetic mutations. Its targeted mechanism of action involves exon skipping, which restores the production of functional dystrophin protein. As a high-value biopharmaceutical, the supply chain integrity, comprising raw materials, manufacturing capabilities, and distribution channels, is crucial for ensuring uninterrupted patient access. This article provides an in-depth analysis of the primary suppliers involved in the production and delivery of AMONDYS 45, examining upstream raw material providers, manufacturing partners, and distribution channels.

---

Raw Material Suppliers and Key Inputs

The manufacturing of antisense oligonucleotides (ASOs) like AMONDYS 45 hinges on high-purity chemical synthesis and specialized raw materials. Key inputs include nucleotide phosphoramidites, oligonucleotide synthesis reagents, and sterile bioprocessing components.

1. Nucleotide and Phosphoramidite Suppliers

The foundation of ASO synthesis involves phosphoramidites, which are specialized nucleotide building blocks.

• Thermo Fisher Scientific: A principal supplier of high-quality phosphoramidites, oligonucleotide synthesis reagents, and related chemicals. Thermo Fisher’s reagents adhere to rigorous pharmaceutical standards, supporting scaled production for clinical and commercial distribution.

• Agilent Technologies: Offers oligonucleotide synthesis platforms and high-quality chemical reagents. Agilent’s compounds are vital for producing consistent and high-purity ASOs such as casimersen.

• ChemGenes Corporation: Supplies custom phosphoramidites and modified nucleotides tailored for therapeutic applications, supporting bespoke synthesis requirements.

2. Good Manufacturing Practice (GMP) Grade Reagents

Suppliers of GMP-grade reagents ensure compliance with regulatory standards for clinical manufacturing:

• Sigma-Aldrich (part of Merck Group): Known for a broad portfolio of GMP-grade oligonucleotides and manufacturing reagents essential for early-stage and clinical production of AMONDYS 45.

• Jena Bioscience: Provides modified nucleotides and oligonucleotide synthesis tools that meet stringent pharma standards.

---

Manufacturing Partners

The production of AMONDYS 45 involves complex facilities with capabilities aligned with FDA and EMA regulations.

1. Sarepta Therapeutics' Manufacturing Facilities

Sarepta maintains in-house manufacturing capabilities, including:

• Research and Development (R&D) facilities: Focused on process development, scale-up, and analytical validation. These facilities are equipped to produce early-phase clinical batches.

• Commercial manufacturing units: The company owns or partners with GMP-certified manufacturing plants capable of high-volume production of ASOs, ensuring supply scalability.

2. Contract Manufacturing Organizations (CMOs)

Given the complexity and cost of oligonucleotide manufacturing, Sarepta collaborates with specialized CMOs:

• CordenPharma (a Bain Capital portfolio company): Known for its cGMP manufacturing expertise in oligonucleotide synthesis, they produce clinical and commercial batches of AMONDYS 45, leveraging advanced phosphoramidite chemistry and purification techniques.

• Viva Biotech: Provides contract synthesis, particularly tailored for high-purity requirements, ensuring seamless scale-up from pilot to commercial production.

• Eurofins Scientific: Offers analytical and quality control testing to ensure batch consistency, process validation, and regulatory compliance.

Distribution and Logistics Channels

Supply chain management for AMONDYS 45 extends beyond production to encompass global distribution.

1. Distribution Partners and Logistics

• Sarepta’s Distribution Network: Sarepta manages or contracts with specialized pharmaceutical logistics firms to ensure cold chain integrity, regulatory compliance, and timely delivery to healthcare providers.

• Third-party Logistics (3PL) Providers: Companies like DHL, FedEx, and UPS facilitate global distribution, adhering to temperature-controlled conditions mandated for oligonucleotide stability.

2. Regulatory and Import/Export Facilitators

• Customs and Regulatory Agencies: Collaboration with regulatory bodies like the FDA and EMA ensures controlled import/export, compliance with licensing, and traceability.

• Regional Distributors: Partnered with regional specialty pharmacies and hospitals to facilitate patient access, especially in areas with limited infrastructure.

---

Supply Chain Challenges and Considerations

Despite a robust supplier network, several challenges impact the supply of AMONDYS 45:

• Raw Material Scarcity: Limited suppliers of GMP-grade phosphoramidites and modified nucleotides can create bottlenecks.

• Manufacturing Capacity Constraints: The highly specialized nature of oligonucleotide manufacturing demands significant lead times and strict quality adherence.

• Cold Chain Logistics: Ensuring temperature stability during global distribution remains critical, especially in regions with limited infrastructure.

• Regulatory Hurdles: Variations in regulatory requirements across countries can delay approvals and distribution channels.

---

Future Outlook

The growing demand for personalized therapies like AMONDYS 45 stimulates investment in supply chain resilience:

• Expanding Raw Material Supplier Base: Companies are incentivizing new entrants and diversifying sources to mitigate supply risks.

• Technological Innovations: Advancements in synthetic chemistry and continuous manufacturing processes are expected to improve scalability and reduce costs.

• Strategic Partnerships: Sarepta and other stakeholders are likely to enter new collaborations with contract manufacturing and distribution firms to ensure steady supply amid expanding indications.

---

Key Takeaways

• The supply chain for AMONDYS 45 involves a diverse network, with critical raw material suppliers including Thermo Fisher Scientific, Agilent Technologies, and ChemGenes.

• Manufacturing is predominantly carried out by Sarepta’s facilities and specialized CMOs such as CordenPharma, ensuring high-quality, scalable production.

• Distribution relies on a combination of internal logistics capacity and third-party logistics providers, emphasizing cold chain integrity.

• Supply chain resilience hinges on diversified raw material sourcing, advanced manufacturing capabilities, and robust logistics networks.

• Ongoing investment and technological innovation are essential to address future demand and mitigate supply risks.

---

FAQs

1. Who are the main raw material suppliers for AMONDYS 45?
Key suppliers include Thermo Fisher Scientific, Agilent Technologies, and ChemGenes Corporation, providing high-purity phosphoramidites and oligonucleotide synthesis reagents under GMP conditions.

2. Does Sarepta manufacture AMONDYS 45 in-house?
Sarepta has its own manufacturing facilities but exclusively partners with Contract Manufacturing Organizations like CordenPharma for large-scale production, ensuring capacity and regulatory compliance.

3. What logistics challenges exist in distributing AMONDYS 45 globally?
Maintaining cold chain logistics, ensuring timely delivery across regions, and navigating regulatory differences are primary logistical challenges.

4. Are there any alternative suppliers or manufacturers in development?
The growing demand encourages diversification; companies like Jena Bioscience and Viva Biotech are expanding their offerings to alleviate raw material shortages and increase manufacturing capacity.

5. How is supply chain risk managed for AMONDYS 45?
Through diversified sourcing, strategic partnerships, and investment in manufacturing scalability, companies aim to mitigate risks associated with supply disruptions.

---

References

[1] Sarepta Therapeutics. “FDA Approves EXONDY (Eteplirsen) for Duchenne Muscular Dystrophy.” FDA Website, 2016.
[2] U.S. Food and Drug Administration. “Drug Approval Package: Casimersen (AMONDYS 45).” FDA, 2021.
[3] ChemGenes Corporation. Product Portfolio.
[4] CordenPharma. Contract Manufacturing Capabilities.
[5] Agilent Technologies. Oligonucleotide Synthesis Reagents.